Modelling Mutation to a Cytotoxic T-Lymphocyte HIV Vaccine

Mathematical Population Studies

Volumn 18, Issue 2, 2011, Pages 122-149

  Konrad, Bernhard P ^a   Vaidya, Naveen K ^b   Smith, Robert J ^c  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Adherence; Cytotoxic T lymphocytes; Escape mutation; Fitness cost; Impulsive differential equations; Vaccination

Indexed keywords

DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; MUTATION; VACCINATION; VACCINE; VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 79957552723     PISSN: 08898480     EISSN: 1547724X     Source Type: Journal    
DOI: 10.1080/08898480.2011.564566     Document Type: Article

References (30)

1. Altice, F.L. and Friedland, G.H. (1998). The era of adherence to HIV therapy. Annals of Internal Medicine, 129: 503-505.
2. Amara, R.R., Villinger, F., Altman, J.D., et al. (2001). Control of a mucosal challenge and prevention of clinical AIDS in rhesus monkeys by a multiprotein DNA/MVA vaccine. Science, 292: 69-74.
3. Amara, R.R., Villinger, F., Altman, J.D., et al. (2002). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine, 20: 1949-1955
4. Asquith, B. (2008). The evolutionary selective advantage of HIV-1 escape variants and the contribution of escape to the HLA-associated risk of AIDS progression. PLoS One, 3(10): e3486.
5. Ball, C.L., Gilchrist, M.A., and Coombs, D. (2007). Modeling within-host evolution of HIV: Mutation, competition and strain replacement. Bulletin of Mathematical Biology, 69: 2361-2385.
6. Barouch, D.H., Kunstman, J., Glowczwskie, J., et al. (2003). Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNAvaccinated rhesus monkeys. Journal of Virology, 77: 7367-7375.
7. Barouch, D.H., Kunstman, J., Kuroda, M.J., et al. (2002). Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature, 415: 335-339.
8. Barouch, D.H., Santra, S., Schmitz, J.E., et al. (2000). Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science, 290: 486-492.
9. Bartlett, J.A. (2002), Addressing the challenges of adherence. Journal of Acquired Immune Deficiency Syndrome, 29(Suppl. 1): 2-10.
10. Boerde, R.J. and Perelson, A.S. (1998). Target cell limited and immune control models of HIV infection: A comparison. Journal of Theoretical Biology, 190: 201-214.
11. Collins, K.L., Chen, B.K., Kalams, S.A., et al. (1998). HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature, 391: 397-401.
12. Essunger, P. and Perelson, A.S. (1994). Modeling HIV infection of CD4+ T-cell subpopulations. Journal of Theoretical Biology, 170(4): 367-391.
13. Gerdil, C. (2003). The annual production cycle for influenza vaccine. Vaccine, 21(16): 1776-1779.
14. Goulder, P.J.R. and Watkins, D.I. (2004). HIV and SIV CTL escape: Implications for vaccine design. Nature Reviews Immunology, 4: 630-640.
15. Jamieson, B.D., Yang, O.O., Hultin, L., et al. (2003). Epitope escape mutation and decay of human immunodeficiency virus type 1-specific CTL responses. Journal of Immunology, 171: 5372-5379.
16. Jin, X., Bauer, D.E., Tuttleton, S.E., et al. (1999). Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. Journal of Experimental Medicine, 189: 991-998.
17. Klein, M.R., van der Burg, S.H., Pontesilli, O., et al. (1998). Cytotoxic T lymphocytes in HIV-1 infection: A killing paradox? Immunology Today, 19(7): 317-324.
18. Korthals Altes, H., Wodarz, D., and Jansen, V.A.A. (2002). The dual role of CD4 T helper cells in the infection dynamics of HIV and their importance for vaccination. Journal of Theoretical Biology, 214(4): 633-646.
19. Mansky, L.M. and Temin, H.M. (1995). Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. Journal of Virology, 69: 5087-5094.
20. Miron R.E and Smith, R.J. (2010). Modelling imperfect adherence to HIV induction therapy. BMC Infectious Diseases, 10: 6.
21. Perelson, A.S. and Nelson, P.W. (1999). Mathematical analysis of HIV-1 dynamics in vivo. SIAM Review, 41: 3-44.
22. Perelson, A.S., Neumann, A.U., Markowitz, M., et al. (1996). HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifespan, and viral generation time. Science, 271: 1582-1586.
23. Rong, L., Feng, Z., and Perelson, A.S. (2007). Emergence of HIV-1 drug resistance during antiretroviral treatment. Bulletin of Mathematical Biology, 69: 2027-206
24. Schmitz, J.E., Kuroda, M.J., Santra, S., et al. (1999). Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science, 283: 857-860.
25. Smith, R.J. (2006). Adherence to antiretroviral HIV drugs: How many doses can you miss before resistance emerges? Proceedings of the Royal Society B, 273: 617-624.
26. Smith, R.J., Okano, J.T., Kahn, J.S., et al. (2010). Evolutionary dynamics of complex networks of HIV drug-resistant strains: The case of San Francisco. Science, 327(5966): 697-701.
27. Smith, R.J. and Schwartz, E.J. (2008). Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: How often should you vaccinate and how strong should the vaccine be? Mathematical Biosciences, 212: 180-187.
28. Smith, R.J. and Wahl, L.M. (2005). Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. Bulletin of Mathematical Biology, 64(4): 783-813.
29. Smith, S.M. (2004). HIV CTL escape: At what cost? Retrovirology, 1: 8.
30. Wolkowicz, G.S.K. and Lu, Z. (1992). Global dynamics of a mathematical model of competition in the chemostat: General response functions and differential death rates. SIAM Journal on Applied Mathematics, 52(1): 222-233.